4.6 Article

Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1

Journal

PLOS ONE
Volume 11, Issue 7, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0160344

Keywords

-

Funding

  1. Fonds recherche Quebec-Sante
  2. Canadian Institute for Health Research (CIHR)
  3. Deutsche Krebshilfe
  4. Jakstadt-foundation
  5. CIHR [MOP - 111011, MOP-106427]

Ask authors/readers for more resources

A regulatory circuit that controls myeloid versus B lymphoid cell fate in hematopoietic progenitors has been proposed, in which a network of the transcription factors Egr1/2, Nab, Gfi1 and PU.1 forms the core element. Here we show that a direct link between Gfi1, the transcription factor E2A and its inhibitor Id1 is a critical element of this regulatory circuit. Our data suggest that a certain threshold of Gfi1 is required to gauge E2A activity by adjusting levels of Id1 in multipotent progenitors, which are the first bipotential myeloid/lymphoidrestricted progeny of hematopoietic stem cells. If Gfi1 levels are high, Id1 is repressed enabling E2A to activate a specific set of B lineage genes by binding to regulatory elements for example the IL7 receptor gene. If Gfi1 levels fall below a threshold, Id1 expression increases and renders E2A unable to function, which prevents hematopoietic progenitors from engaging along the B lymphoid lineage.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM

Friederike Bachmann, Martin Schreder, Monika Engelhardt, Christian Langer, Denise Wolleschak, Lars Olof Muegge, Heinz Duerk, Kerstin Schaefer-Eckart, Igor Wolfgang Blau, Martin Gramatzki, Peter Liebisch, Matthias Grube, Ivana Metzler, Florian Bassermann, Bernd Metzner, Christoph Roellig, Bernd Hertenstein, Cyrus Khandanpour, Tobias Dechow, Holger Hebart, Wolfram Jung, Sebastian Theurich, Georg Maschmeyer, Hans Salwender, Georg Hess, Max Bittrich, Leo Rasche, Annamaria Brioli, Kai-Uwe Eckardt, Christian Straka, Swantje Held, Hermann Einsele, Stefan Knop

Summary: Renal insufficiency is common in newly diagnosed multiple myeloma, and it can be caused by the disease itself, medical interventions, or infections. Quick disease control with effective therapy can help improve renal function. Different three-drug regimens for initial myeloma treatment had a positive impact on kidney function, but some patients may experience worsening renal function following induction therapy.

CANCERS (2021)

Article Hematology

Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells

Helal Mohammed Mohammed Ahmed, Subbaiah Chary Nimmagadda, Yahya S. Al-Matary, Maren Fiori, Tobias May, Daria Frank, Pradeep Kumar Patnana, Christian Recher, Christoph Schliemann, Jan-Henrik Mikesch, Thorsten Koenig, Frank Rosenbauer, Wolfgang Hartmann, Jan Tuckermann, Ulrich Duhrsen, Wei Lanying, Martin Dugas, Bertram Opalka, Georg Lenz, Cyrus Khandanpour

Summary: This study showed functional differences between AML MSCs and HD MSCs, with Notch signaling in AML MSCs enhancing AML cell proliferation, while dexamethasone or Notch inhibitors could disrupt the interaction between AML cells and AML MSCs, improving treatment outcomes in AML patients.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Article Biochemistry & Molecular Biology

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)

Xiaoqing Xie, Daria Frank, Pradeep Kumar Patnana, Judith Schuette, Yahya Al-Matary, Longlong Liu, Lanying Wei, Martin Dugas, Julian Varghese, Subbaiah Chary Nimmagadda, Cyrus Khandanpour

Summary: The study identified a therapeutic role for curcumin treatment in delaying the expansion of GFI1-36N or -KD, NUP98-HODXD13 leukemic cells and prolonging AML-free survival.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity

Maria V. Yusenko, Abhiruchi Biyanee, Daria Frank, Leonhard H. F. Koehler, Mattias K. Andersson, Cyrus Khandanpour, Rainer Schobert, Goeran Stenman, Bernhard Biersack, Karl-Heinz Klempnauer

Summary: This study introduces a novel MYB inhibitory compound called Bcr-TMP, which shows potential therapeutic effects on leukemias and cancers dependent on deregulated MYB activity. Bcr-TMP down-regulates MYB target genes, induces cell death and differentiation, and exhibits stronger anti-proliferative effects on MYB-addicted primary cells. Additionally, Bcr-TMP acts through p300 and has anti-microtubule activity. Further research is needed to understand its mechanism of action and therapeutic potential.

CANCERS (2022)

Article Oncology

Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia

Daniela V. Wenge, Klaus Wethmar, Corinna A. Klar, Hedwig Kolve, Tim Sauer, Linus Angenendt, Georg Evers, Simon Call, Andrea Kerkhoff, Cyrus Khandanpour, Torsten Kessler, Rolf Mesters, Christoph Schliemann, Jan-Henrik Mikesch, Christian Reicherts, Monika Brueggemann, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes

Summary: This retrospective study evaluated the treatment outcomes of 93 elderly patients with acute lymphoblastic leukemia who received intensive chemotherapy. The study identified age and performance status as risk factors for poor outcomes, while intensity of treatment and disease characteristics did not significantly affect overall survival. The results suggest that intensive treatment of elderly ALL patients is feasible but associated with significant toxicity.

CANCERS (2022)

Article Oncology

High Metabolic Dependence on Oxidative Phosphorylation Drives Sensitivity to Metformin Treatment in MLL/AF9 Acute Myeloid Leukemia

Longlong Liu, Pradeep Kumar Patnana, Xiaoqing Xie, Daria Frank, Subbaiah Chary Nimmagadda, Annegret Rosemann, Marie Liebmann, Luisa Klotz, Bertram Opalka, Cyrus Khandanpour

Summary: This study demonstrates that AML cells with an MLL/AF9 genotype have a high dependency on oxidative phosphorylation and could be targeted for therapy using metformin.

CANCERS (2022)

Article Oncology

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis

Hira Mian, Christine Eisfeld, Christopher P. Venner, Esther Masih-Khan, Moustafa Kardjadj, Victor H. Jimenez-Zepeda, Cyrus Khandanpour, Georg Lenz, Arleigh McCurdy, Michael Sebag, Kevin Song, Richard LeBlanc, Darrell White, Julie Stakiw, Anthony Reiman, Martha Louzada, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece

Summary: Daratumumab-containing therapies are effective regimens in patients progressing on lenalidomide maintenance.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells

Daria Frank, Ramkumar Moorthy, John C. Widen, Cyrus Khandanpour, Daniel A. Harki, Karl-Heinz Klempnauer, Luca Abdel Ghani, Maria V. Yusenko, Wolfgang Doerner

Summary: C/EBP β is a transcription factor that cooperates with MYB to maintain proliferation and differentiation block of AML cells. A synthetic analog of helenalin inhibits C/EBP β by covalently binding to cysteine residues in the transactivation domain, leading to enhanced differentiation, cell death, and reduced self-renewal potential of AML cells. Gene expression profiling confirms the relevance of C/EBP β as a therapeutic target. However, further development is needed to improve the effectiveness of the synthetic analog as a C/EBP β inhibitor.

CANCER LETTERS (2022)

Article Oncology

GFI1B acts as a metabolic regulator in hematopoiesis and acute myeloid leukemia

Longlong Liu, Pradeep Kumar Patnana, Xiaoqing Xie, Daria Frank, Subbaiah Chary Nimmagadda, Minhua Su, Donghua Zhang, Thorsten Koenig, Frank Rosenbauer, Marie Liebmann, Luisa Klotz, Wendan Xu, Jan Vorwerk, Felix Neumann, Jana Huve, Andreas Unger, Jurgen Gunther Okun, Bertram Opalka, Cyrus Khandanpour

Summary: Recent studies have revealed the important role of transcription factor GFI1B in metabolic regulation during hematopoiesis and leukemia development. Gfi1b deletion leads to activation of mitochondrial respiration and alteration of energy metabolism towards oxidative phosphorylation (OXPHOS). Gfi1b also epigenetically regulates multiple genes involved in fatty acid oxidation (FAO). The correlation between Gfi1b expression level and metabolic phenotype is influenced by genetic variations in AML cells. Inhibition of FAO or OXPHOS significantly hinders leukemia progression, and Gfi1b-deficient AML cells are more sensitive to drugs targeting OXPHOS and FAO, suggesting new potential therapeutic strategies.

LEUKEMIA (2022)

Article Oncology

Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis

Evgenii Shumilov, Lena Aperdannier, Nicole Schmidt, Christoph Szuszies, Albrecht Neesse, Petra Hoffknecht, Cyrus Khandanpour, Jan-Henrik Mikesch, Matthias Stelljes, Goeran Ramin Boeckel, Phil-Robin Tepasse, Lea Reitnauer, Raphael Koch, Justin Hasenkamp, Ulrike Bacher, Simone Scheithauer, Lorenz Truemper, Norbert Schmitz, Gerald Wulf, Andrea Kerkhoff

Summary: This study investigated the impact of COVID-19 vaccines on SARS-CoV-2 infections and the course of COVID-19 in cancer patients. The results showed that vaccinated cancer patients had a milder course of COVID-19 and reduced hospitalization time and mortality compared to non-vaccinated patients. These findings provide evidence for the significant benefits of COVID-19 vaccines for cancer patients.

CANCERS (2022)

Article Oncology

Inhibiting PI3K-AKT-mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells

Luca Heinemann, Klara Maria Moellers, Helal Mohammed Mohammed Ahmed, Lanying Wei, Kaiyan Sun, Subbaiah Chary Nimmagadda, Daria Frank, Anja Baumann, Alexandra M. Poos, Martin Dugas, Julian Varghese, Marc-Steffen Raab, Cyrus Khandanpour

Summary: This study investigated the gene differences between MSCs from multiple myeloma patients and those from other diseases, showing an enrichment of the PI3K-AKT-mTOR signaling pathway in MM-associated MSCs and the inhibitory effect of Pictilisib on these cells.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

Nicole Baeumer, Annika Scheller, Lisa Wittmann, Andreas Faust, Mara Apel, Subbaiah Chary Nimmagadda, Christiane Geyer, Katharina Grunert, Neele Kellmann, Matthias Peipp, Sareetha Kailayangiri, Matias Ezequiel Gutierrez Suburu, Cristian A. Strassert, Mathias Schenk, Lilo Greune, Christian Rueter, Petra Dersch, Wolfgang Hartmann, Claudia Rossig, Dario Neri, Carsten Mueller-Tidow, Christian Schwoeppe, Christoph Schliemann, Cyrus Khandanpour, Georg Lenz, Wolfgang E. Berdel, Sebastian Baeumer

Summary: This study developed a new experimental platform technology for targeting molecular oncogenes in AML using electrostatic nanocarriers. It showed therapeutic activity against AML in cell lines and animal models, specifically targeting mutated genes.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Article Oncology

Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario

Carolin Krekeler, Lea Reitnauer, Ulrike Bacher, Cyrus Khandanpour, Leander Steger, Goran Ramin Boeckel, Justine Klosner, Phil-Robin Tepasse, Marcel Kemper, Marc Tim Hennies, Rolf Mesters, Matthias Stelljes, Norbert Schmitz, Andrea Kerkhoff, Christoph Schliemann, Jan-Henrik Mikesch, Nicole Schmidt, Georg Lenz, Annalen Bleckmann, Evgenii Shumilov

Summary: This study provides data on the efficacy of COVID-19 prime-boost vaccines in patients with hematologic malignancies and offers guidance for managing weak or failed responses to the vaccines. The study found that 55% of the patients achieved seroconversion after vaccination. Factors such as age, lymphocytopenia, ongoing treatment, and anti-CD20 B-cell depletion were predictors of booster failure. Passive immunization was associated with a lower risk of breakthrough infections.

CANCERS (2022)

Article Oncology

Radiotherapy in Combination with Systemic Therapy for Multiple Myeloma-A Critical Toxicity Evaluation in the Modern Treatment Era

Michael Oertel, Tom Schlusemann, Evgenii Shumilov, Gabriele Reinartz, Anne Bremer, Stephan Rehn, Georg Lenz, Cyrus Khandanpour, Hans Theodor Eich

Summary: This study evaluated the tolerability of concurrent radiotherapy and targeted therapy. The results showed that radiotherapy is safe and feasible in the treatment of multiple myeloma, but careful monitoring of potential toxicities is necessary.

CANCERS (2023)

Article Oncology

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial

Lisa B. Leypoldt, Maria Gavriatopoulou, Britta Besemer, Hans Salwender, Marc S. Raab, Axel Nogai, Cyrus Khandanpour, Volker Runde, Anna Jauch, Manola Zago, Peter Martus, Hartmut Goldschmidt, Carsten Bokemeyer, Meletios A. Dimopoulos, Katja C. Weisel

Summary: This study evaluated the safety and efficacy of daratumumab, bortezomib, and dexamethasone in multiple myeloma patients with severe renal function impairment. The treatment showed an overall response rate of 67% and improved renal function in patients. This study suggests that this treatment regimen could be considered in the clinical practice for multiple myeloma patients with severe renal function impairment.

CANCERS (2023)

No Data Available